Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
Identifieur interne : 004406 ( PubMed/Corpus ); précédent : 004405; suivant : 004407Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
Auteurs : Mary Chester Wasko ; Elizabeth C. Hsia ; Bruce Kirkham ; Pierre-Jean Touboul ; Roy Fleischmann ; Mark C. Genovese ; Eric L. Matteson ; Jiandong Lu ; Weichun Xu ; Mahboob U. RahmanSource :
- Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases [ 1536-7355 ] ; 2014.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (pharmacology), Antibodies, Monoclonal (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis (drug therapy), Cardiovascular Diseases (diagnostic imaging), Cardiovascular Diseases (epidemiology), Carotid Arteries (diagnostic imaging), Carotid Arteries (drug effects), Carotid Artery Diseases (diagnostic imaging), Carotid Artery Diseases (epidemiology), Carotid Intima-Media Thickness, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Incidence, Male, Methotrexate (therapeutic use), Middle Aged, Risk Factors, Treatment Outcome, Ultrasonography, Interventional.
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal.
- chemical , pharmacology : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal, Antirheumatic Agents, Methotrexate.
- diagnostic imaging : Cardiovascular Diseases, Carotid Arteries, Carotid Artery Diseases.
- drug effects : Carotid Arteries.
- drug therapy : Arthritis.
- epidemiology : Cardiovascular Diseases, Carotid Artery Diseases.
- Carotid Intima-Media Thickness, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Risk Factors, Treatment Outcome, Ultrasonography, Interventional.
Abstract
The objective of this study was to assess the effect of golimumab on carotid ultrasound measures and cardiovascular serious adverse events (SAEs) in patients with inflammatory arthritides.
DOI: 10.1097/RHU.0000000000000053
PubMed: 24356481
Links to Exploration step
pubmed:24356481Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.</title><author><name sortKey="Wasko, Mary Chester" sort="Wasko, Mary Chester" uniqKey="Wasko M" first="Mary Chester" last="Wasko">Mary Chester Wasko</name><affiliation><nlm:affiliation>From the *Allegheny Singer Research Institute, West Penn Allegheny Health System; †Temple University School of Medicine-Pittsburgh Campus, Pittsburgh, PA; ‡Janssen Research & Development, LLC, Spring House, PA; §University of Pennsylvania School of Medicine, Philadelphia, PA; ∥Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; ¶Department of Neurology and Stroke Center, Hôpital Bichat, Paris, France; #Metroplex Clinical Research Center, Dallas, TX; **Stanford University, Palo Alto, CA; and ††Mayo Clinic College of Medicine, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Hsia, Elizabeth C" sort="Hsia, Elizabeth C" uniqKey="Hsia E" first="Elizabeth C" last="Hsia">Elizabeth C. Hsia</name></author><author><name sortKey="Kirkham, Bruce" sort="Kirkham, Bruce" uniqKey="Kirkham B" first="Bruce" last="Kirkham">Bruce Kirkham</name></author><author><name sortKey="Touboul, Pierre Jean" sort="Touboul, Pierre Jean" uniqKey="Touboul P" first="Pierre-Jean" last="Touboul">Pierre-Jean Touboul</name></author><author><name sortKey="Fleischmann, Roy" sort="Fleischmann, Roy" uniqKey="Fleischmann R" first="Roy" last="Fleischmann">Roy Fleischmann</name></author><author><name sortKey="Genovese, Mark C" sort="Genovese, Mark C" uniqKey="Genovese M" first="Mark C" last="Genovese">Mark C. Genovese</name></author><author><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L" last="Matteson">Eric L. Matteson</name></author><author><name sortKey="Lu, Jiandong" sort="Lu, Jiandong" uniqKey="Lu J" first="Jiandong" last="Lu">Jiandong Lu</name></author><author><name sortKey="Xu, Weichun" sort="Xu, Weichun" uniqKey="Xu W" first="Weichun" last="Xu">Weichun Xu</name></author><author><name sortKey="Rahman, Mahboob U" sort="Rahman, Mahboob U" uniqKey="Rahman M" first="Mahboob U" last="Rahman">Mahboob U. Rahman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24356481</idno><idno type="pmid">24356481</idno><idno type="doi">10.1097/RHU.0000000000000053</idno><idno type="wicri:Area/PubMed/Corpus">004406</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004406</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.</title><author><name sortKey="Wasko, Mary Chester" sort="Wasko, Mary Chester" uniqKey="Wasko M" first="Mary Chester" last="Wasko">Mary Chester Wasko</name><affiliation><nlm:affiliation>From the *Allegheny Singer Research Institute, West Penn Allegheny Health System; †Temple University School of Medicine-Pittsburgh Campus, Pittsburgh, PA; ‡Janssen Research & Development, LLC, Spring House, PA; §University of Pennsylvania School of Medicine, Philadelphia, PA; ∥Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; ¶Department of Neurology and Stroke Center, Hôpital Bichat, Paris, France; #Metroplex Clinical Research Center, Dallas, TX; **Stanford University, Palo Alto, CA; and ††Mayo Clinic College of Medicine, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Hsia, Elizabeth C" sort="Hsia, Elizabeth C" uniqKey="Hsia E" first="Elizabeth C" last="Hsia">Elizabeth C. Hsia</name></author><author><name sortKey="Kirkham, Bruce" sort="Kirkham, Bruce" uniqKey="Kirkham B" first="Bruce" last="Kirkham">Bruce Kirkham</name></author><author><name sortKey="Touboul, Pierre Jean" sort="Touboul, Pierre Jean" uniqKey="Touboul P" first="Pierre-Jean" last="Touboul">Pierre-Jean Touboul</name></author><author><name sortKey="Fleischmann, Roy" sort="Fleischmann, Roy" uniqKey="Fleischmann R" first="Roy" last="Fleischmann">Roy Fleischmann</name></author><author><name sortKey="Genovese, Mark C" sort="Genovese, Mark C" uniqKey="Genovese M" first="Mark C" last="Genovese">Mark C. Genovese</name></author><author><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L" last="Matteson">Eric L. Matteson</name></author><author><name sortKey="Lu, Jiandong" sort="Lu, Jiandong" uniqKey="Lu J" first="Jiandong" last="Lu">Jiandong Lu</name></author><author><name sortKey="Xu, Weichun" sort="Xu, Weichun" uniqKey="Xu W" first="Weichun" last="Xu">Weichun Xu</name></author><author><name sortKey="Rahman, Mahboob U" sort="Rahman, Mahboob U" uniqKey="Rahman M" first="Mahboob U" last="Rahman">Mahboob U. Rahman</name></author></analytic><series><title level="j">Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases</title><idno type="eISSN">1536-7355</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis (drug therapy)</term><term>Cardiovascular Diseases (diagnostic imaging)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Carotid Arteries (diagnostic imaging)</term><term>Carotid Arteries (drug effects)</term><term>Carotid Artery Diseases (diagnostic imaging)</term><term>Carotid Artery Diseases (epidemiology)</term><term>Carotid Intima-Media Thickness</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Risk Factors</term><term>Treatment Outcome</term><term>Ultrasonography, Interventional</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antirheumatic Agents</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Cardiovascular Diseases</term><term>Carotid Arteries</term><term>Carotid Artery Diseases</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Carotid Arteries</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Carotid Artery Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Carotid Intima-Media Thickness</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Treatment Outcome</term><term>Ultrasonography, Interventional</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to assess the effect of golimumab on carotid ultrasound measures and cardiovascular serious adverse events (SAEs) in patients with inflammatory arthritides.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24356481</PMID><DateCreated><Year>2013</Year><Month>12</Month><Day>23</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-7355</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases</Title><ISOAbbreviation>J Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.</ArticleTitle><Pagination><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/RHU.0000000000000053</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to assess the effect of golimumab on carotid ultrasound measures and cardiovascular serious adverse events (SAEs) in patients with inflammatory arthritides.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An exploratory carotid artery ultrasound substudy was performed in the GO-BEFORE study of methotrexate (MTX)-naive rheumatoid arthritis patients, with ultrasounds performed at weeks 0, 24, and 52 to measure common carotid artery intima-media thickness, distensibility coefficient, interadventitial diameter, and plaque count. Cardiovascular SAEs reported over 2 years of follow-up were assessed in 5 golimumab phase 3 clinical trials of patients with rheumatoid arthritis (GO-BEFORE, GO-FORWARD, and GO-AFTER), psoriatic arthritis (GO-REVEAL), and ankylosing spondylitis (GO-RAISE). In GO-BEFORE and GO-FORWARD, patients received placebo + MTX, golimumab 50 mg + MTX, or golimumab 100 mg +/- MTX at baseline and every 4 weeks; in the other 3 trials, patients received placebo or golimumab 50 or 100 mg.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The carotid ultrasound substudy showed inconsistent changes in common carotid artery intima-media thickness in the golimumab + MTX groups over time, and there was large variability in the measurements. Increases in interadventitial diameter were observed in the golimumab 100 mg + placebo group, but not in the golimumab + MTX groups. There were no significant differences in the distensibility coefficient and plaque count between the golimumab and placebo groups. Very few patients overall experienced a cardiovascular SAE, and the incidence of cardiovascular SAEs was not statistically different between the golimumab and placebo groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of the carotid ultrasound substudy were inconclusive, and no increase or decrease in cardiovascular SAEs was observed following 2 years of treatment with golimumab with or without MTX.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wasko</LastName><ForeName>Mary Chester</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>From the *Allegheny Singer Research Institute, West Penn Allegheny Health System; †Temple University School of Medicine-Pittsburgh Campus, Pittsburgh, PA; ‡Janssen Research & Development, LLC, Spring House, PA; §University of Pennsylvania School of Medicine, Philadelphia, PA; ∥Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; ¶Department of Neurology and Stroke Center, Hôpital Bichat, Paris, France; #Metroplex Clinical Research Center, Dallas, TX; **Stanford University, Palo Alto, CA; and ††Mayo Clinic College of Medicine, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsia</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Kirkham</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Touboul</LastName><ForeName>Pierre-Jean</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Fleischmann</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Genovese</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Matteson</LastName><ForeName>Eric L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jiandong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Weichun</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Mahboob U</ForeName><Initials>MU</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Rheumatol</MedlineTA><NlmUniqueID>9518034</NlmUniqueID><ISSNLinking>1076-1608</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>91X1KLU43E</RegistryNumber><NameOfSubstance UI="C529000">golimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="N">Arthritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002339" MajorTopicYN="N">Carotid Arteries</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002340" MajorTopicYN="N">Carotid Artery Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059168" MajorTopicYN="Y">Carotid Intima-Media Thickness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018084" MajorTopicYN="N">Ultrasonography, Interventional</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24356481</ArticleId><ArticleId IdType="doi">10.1097/RHU.0000000000000053</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004406 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004406 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24356481
|texte= Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24356481" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |